Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II
Executive Summary
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
You may also be interested in...
Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
Amgen Continues To Feel COVID-19 Sales Impact In Q1
Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.
Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.